柳氮磺胺吡啶与羟氯喹治疗类风湿关节炎的双盲对照研究：柳氮磺胺吡啶早期疗效证据
A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine.
作者信息
Nuver-Zwart I H, van Riel P L, van de Putte L B, Gribnau F W
机构信息
Department of Rheumatology, University Hospital, Nijmegen, The Netherlands.
出版信息
Ann Rheum Dis. 1989 May;48(5):389-95. doi: 10.1136/ard.48.5.389.
Abstract
In a double blind, single observer, 48 week study the effects of sulphasalazine (2 g daily) and hydroxychloroquine (400 mg daily months 0-6, thereafter 200 mg daily) were compared in 60 patients with definite or classical rheumatoid arthritis. They had not been treated previously with second line drugs. The onset of response with sulphasalazine was earlier than with hydroxychloroquine. After 48 weeks a comparison of the treatments showed no statistically significant differences in disease activity variables. Adverse reaction was the main reason for withdrawal in the sulphasalazine group and lack of efficacy in the hydroxychloroquine group. All adverse reactions, one being agranulocytosis after eight weeks of sulphasalazine treatment, appeared in the first three months of treatment and were completely reversible.
摘要
在一项双盲、单观察者、为期48周的研究中，对60例确诊或典型类风湿性关节炎患者比较了柳氮磺胺吡啶（每日2克）和羟氯喹（0至6个月每日400毫克，此后每日200毫克）的疗效。这些患者此前未接受过二线药物治疗。柳氮磺胺吡啶的起效时间早于羟氯喹。48周后，对两种治疗方法的比较显示，疾病活动变量方面无统计学显著差异。不良反应是柳氮磺胺吡啶组停药的主要原因，而羟氯喹组停药主要是因为缺乏疗效。所有不良反应均出现在治疗的前三个月，且完全可逆，其中一例是柳氮磺胺吡啶治疗八周后出现的粒细胞缺乏症。
相似文献
1
A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine.柳氮磺胺吡啶与羟氯喹治疗类风湿关节炎的双盲对照研究：柳氮磺胺吡啶早期疗效证据
Ann Rheum Dis. 1989 May;48(5):389-95. doi: 10.1136/ard.48.5.389.
2
Hydroxychloroquine and sulphasalazine alone and in combination in rheumatoid arthritis: a randomised double blind trial.羟氯喹和柳氮磺胺吡啶单药及联合用药治疗类风湿关节炎：一项随机双盲试验
Ann Rheum Dis. 1993 Oct;52(10):711-5. doi: 10.1136/ard.52.10.711.
3
Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis.羟氯喹和柳氮磺胺吡啶对类风湿关节炎关节损伤进展的影响。
Lancet. 1989 May 13;1(8646):1036-8. doi: 10.1016/s0140-6736(89)92442-2.
4
Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate.柳氮磺胺吡啶治疗类风湿性关节炎：柳氮磺胺吡啶与安慰剂及金硫代苹果酸钠的双盲对照研究
Br Med J (Clin Res Ed). 1983 Oct 15;287(6399):1102-4. doi: 10.1136/bmj.287.6399.1102.
5
Sulphasalazine versus hydroxychloroquine in rheumatoid arthritis: 3-year follow-up.柳氮磺胺吡啶与羟氯喹治疗类风湿关节炎的3年随访
Lancet. 1990 Mar 3;335(8688):539. doi: 10.1016/0140-6736(90)90771-v.
6
Sensitivity of a Dutch Health Assessment Questionnaire in a trial comparing hydroxychloroquine vs. sulphasalazine.一项比较羟氯喹与柳氮磺胺吡啶的试验中荷兰健康评估问卷的敏感性
Scand J Rheumatol. 1990;19(6):407-12. doi: 10.3109/03009749009097629.
7
Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications.单独使用甲氨蝶呤、柳氮磺胺吡啶和羟氯喹治疗类风湿性关节炎，或三种药物联合使用。
N Engl J Med. 1996 May 16;334(20):1287-91. doi: 10.1056/NEJM199605163342002.
8
Comparison between penicillamine and sulphasalazine in rheumatoid arthritis: Leeds-Birmingham trial.青霉胺与柳氮磺胺吡啶治疗类风湿性关节炎的比较：利兹-伯明翰试验。
Br Med J (Clin Res Ed). 1983 Oct 15;287(6399):1099-102. doi: 10.1136/bmj.287.6399.1099.
9
Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.来氟米特与安慰剂和柳氮磺胺吡啶治疗活动性类风湿关节炎的疗效及安全性比较：一项双盲、随机、多中心试验。欧洲来氟米特研究小组
Lancet. 1999 Jan 23;353(9149):259-66. doi: 10.1016/s0140-6736(98)09403-3.
10
Therapies for active rheumatoid arthritis after methotrexate failure.甲氨蝶呤治疗失败后的活动性类风湿关节炎治疗方法。
N Engl J Med. 2013 Jul 25;369(4):307-18. doi: 10.1056/NEJMoa1303006. Epub 2013 Jun 11.
引用本文的文献
1
Monotreatment With Conventional Antirheumatic Drugs or Glucocorticoids in Rheumatoid Arthritis: A Network Meta-Analysis.类风湿关节炎中单药常规抗风湿药或糖皮质激素治疗：网状 Meta 分析。
JAMA Netw Open. 2023 Oct 2;6(10):e2335950. doi: 10.1001/jamanetworkopen.2023.35950.
2
Recent Clinical and Preclinical Studies of Hydroxychloroquine on RNA Viruses and Chronic Diseases: A Systematic Review.羟氯喹治疗 RNA 病毒和慢性疾病的临床和临床前研究现状：系统评价。
Molecules. 2020 Nov 14;25(22):5318. doi: 10.3390/molecules25225318.
3
Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis.老年类风湿关节炎患者使用传统和新型改善病情抗风湿药物的指南。
Drugs Aging. 2009;26(4):273-93. doi: 10.2165/00002512-200926040-00001.
4
Rheumatoid arthritis.类风湿关节炎
BMJ Clin Evid. 2007 Aug 1;2007:1124.
5
Sulfasalazine: a review of its use in the management of rheumatoid arthritis.柳氮磺胺吡啶：类风湿关节炎治疗应用综述
Drugs. 2005;65(13):1825-49. doi: 10.2165/00003495-200565130-00008.
6
Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. On behalf of the Rheumatic Research Foundation Utrecht, The Netherlands.早期类风湿关节炎的积极治疗：一项随机对照试验。代表荷兰乌得勒支风湿研究基金会。
Ann Rheum Dis. 2000 Jun;59(6):468-77. doi: 10.1136/ard.59.6.468.
7
Sulphasalazine in the treatment of children with chronic arthritis.柳氮磺胺吡啶治疗儿童慢性关节炎
Clin Rheumatol. 1998;17(5):359-63. doi: 10.1007/BF01450892.
8
A double-blind controlled study comparing sulphasalazine with placebo in rheumatoid factor (RF)-negative rheumatoid arthritis.一项在类风湿因子（RF）阴性类风湿关节炎患者中比较柳氮磺胺吡啶与安慰剂的双盲对照研究。
Clin Rheumatol. 1995 Sep;14(5):531-6. doi: 10.1007/BF02208150.
9
Rheumatoid arthritis in the aged. Incidence and optimal management.老年类风湿关节炎。发病率与最佳管理
Drugs Aging. 1993 Nov-Dec;3(6):487-501. doi: 10.2165/00002512-199303060-00003.
10
A prospective analysis of risk factors for the discontinuation of second-line antirheumatic drugs.二线抗风湿药物停用风险因素的前瞻性分析。
Pharm World Sci. 1993 Oct 15;15(5):203-7. doi: 10.1007/BF01880627.
本文引用的文献
1
Salazopyrin in the Treatment of Rheumatoid Arthritis.柳氮磺胺吡啶治疗类风湿关节炎
Ann Rheum Dis. 1949 Sep;8(3):226-31. doi: 10.1136/ard.8.3.226.
2
Hydroxychloroquine sulfate ("plaguenil") in treatment of rheumatoid arthritis.硫酸羟氯喹（“纷乐”）治疗类风湿关节炎。
Arthritis Rheum. 1962 Oct;5:502-12. doi: 10.1002/art.1780050507.
3
Chloroquine in rheumatoid arthritis; a double blindfold trial of treatment for one year.氯喹治疗类风湿性关节炎；一项为期一年的双盲治疗试验。
Ann Rheum Dis. 1960 Sep;19(3):243-50. doi: 10.1136/ard.19.3.243.
4
DIAGNOSTIC criteria for rheumatoid arthritis: 1958 revision by a committee of the American Rheumatism Association.类风湿关节炎的诊断标准：美国风湿病协会委员会1958年修订版。
Ann Rheum Dis. 1959 Mar;18(1):49-51; French transl 51-2; Spanish transl 52-3.
5
A controlled study of chloroquine as an antirheumatic agent.氯喹作为抗风湿药物的对照研究。
Arthritis Rheum. 1958 Aug;1(4):297-312. doi: 10.1002/art.1780010403.
6
A new approach to the analysis of clinical drug trials with withdrawals.一种用于分析有撤药情况的临床药物试验的新方法。
Biometrics. 1980 Dec;36(4):721-7.
7
Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials.抗疟药用于类风湿关节炎长期治疗时的剂量调整
Am J Med. 1983 Jul 18;75(1A):40-5. doi: 10.1016/0002-9343(83)91269-x.
8
The EOG in rheumatoid arthritis.类风湿关节炎中的眼电图
Acta Ophthalmol (Copenh). 1983 Oct;61(5):831-7. doi: 10.1111/j.1755-3768.1983.tb01464.x.
9
The long term effects of sulphasalazine in the treatment of rheumatoid arthritis and a comparative study with penicillamine.柳氮磺胺吡啶治疗类风湿性关节炎的长期疗效及与青霉胺的对比研究。
Clin Rheumatol. 1984 Dec;3(4):473-81. doi: 10.1007/BF02031270.
10
Outcome of attempts to treat rheumatoid arthritis with gold, penicillamine, sulphasalazine, or dapsone.使用金制剂、青霉胺、柳氮磺胺吡啶或氨苯砜治疗类风湿性关节炎的尝试结果。
Ann Rheum Dis. 1984 Jun;43(3):398-401. doi: 10.1136/ard.43.3.398.
Zotero 插件